The PROactive study: some answers, many questions.
Yki-Järvinen
Hannele
H
Department of Medicine, Division of Diabetes, University of Helsinki, PO Box 340, Haartmaninkatu 4, 00290 Helsinki, Finland. ykijarvi@mappi.helsinki.fi
D003327:Coronary Disease / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000517:prevention & control*; D047495:PPAR gamma / Q000819:agonists*; D000077205:Pioglitazone; D020521:Stroke / Q000517:prevention & control*; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077205:Pioglitazone